ACTU (Actuate Therapeutics) Pre-Tax Income : $-27.29 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Actuate Therapeutics's pretax income for the three months ended in Dec. 2024 was $-6.45 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-27.29 Mil. Actuate Therapeutics's pretax margin was %.

Actuate Therapeutics Pre-Tax Income Historical Data

The historical data trend for Actuate Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Pre-Tax Income Chart

Actuate Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Pre-Tax Income

-20.16

-24.75

-27.29

Actuate Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial				-7.61	-8.30	-6.57	-5.97	-6.45

Competitive Comparison of Actuate Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Actuate Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actuate Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Actuate Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Actuate Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-25.161	+	-2.328	+	-0.019	+	0.222	+	0.00099999999999767
	=	-27.29

Actuate Therapeutics's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-6.559	+	0	+	-0.005	+	0.118	+	0
	=	-6.45

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.29 Mil.

Actuate Therapeutics (NAS:ACTU) Pre-Tax Income Explanation

Actuate Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-6.446	/	0
	=	%

Actuate Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Actuate Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.